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The liver-derived hormone hepcidin, a member of the defensin family of antimicrobial
peptides, plays an important role in host defense and innate immunity due to its broad
antibacterial and antiviral properties. Ferritin, an iron storage protein is often associated
with iron deficiency, hypoferritinemia, hypoxia, and immune complications, which are
all significant concerns for systemic infection in Alzheimer’s disease (AD) and Down’s
syndrome (DS) dementia. Serum and post-mortem brain samples were collected from
AD, DS and age-matched control subjects. Serum samples were analyzed with ELISA
for ferritin, hepcidin and IL-6. Additionally, post-mortem brain sections were assessed by
immunohistochemistry for iron-related and inflammatory proteins. A significant increase
in serum hepcidin levels was found in DS, compared to controls and AD subjects
(p < 0.0001). Hepcidin protein was visible in the epithelial cells of choroid plexus,
meningeal macrophages and in the astrocytes close to the endothelium of blood vessels.
Hepcidin co-localized with IL-6, indicating its anti-inflammatory properties. We found
significant correlation between hypoferritinemia and elevated levels of serum hepcidin
in AD and DS. Hepcidin can be transported via macrophages and the majority of
the vesicular hepcidin enters the brain via a compromised blood brain barrier (BBB).
Our findings provide further insight into the molecular implications of the altered iron
metabolism in acute inflammation, and can aid towards the development of preventive
strategies and novel treatments in the fight against neuroinflammation.
Keywords: Alzheimer’s disease, Down’s syndrome dementia, ferritin, hepcidin, choroid plexus, macrophage
activation syndrome, neuroinflammation
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INTRODUCTION
Dementia is a global public health challenge for this generation,
and the most prevalent cause of dementia is late onset
of Alzheimer’s disease (LOAD), a fatal neurodegenerative
disorder characterized by progressive cognitive and functional
impairment associated with memory loss (Hardy et al., 1998).
The two primary pathological hallmarks of AD are senile
plaques (SP), which are extracellular deposits of Aβ derived
from the β-amyloid precursor protein (APP), and neurofibrillary
tangles (NFTs), primarily composed of hyper-phosphorylated
tau (Goedert et al., 1995; Hardy and Selkoe, 2002). Down’s
syndrome (DS) is an aneuploidy due to triplication of all or
part of chromosome 21, where the amyloid precursor protein
(APP) gene is encoded, and plays a key role in the pathogenesis
of AD dementia in DS (Wisniewski et al., 1985; Mann, 1988;
Raha et al., 2013). Although dysfunction of APP processing
is believed to be the key upstream factor in the pathogenesis
of AD (Wilcock, 2012a), neuroinflammation and activation of
innate immunity are considered early events in the genesis of
AD and in DS dementia (Wilcock, 2012b). In DS and in LOAD,
neuroinflammation has been linked to both the exacerbation
of SP and NFT pathology, as well as the clearance of Aβ from
amyloid plaques (Bell et al., 2007; Mawuenyega et al., 2010;
Wildsmith et al., 2013).
The main cell types involved in the brain neuroinflammatory
responses are microglia, astrocytes and to a lesser extent,
the peripheral and meningeal macrophages (Xue and
Streit, 2011; Walsh et al., 2014; Mammana et al., 2018).
Microglia in the vicinity of the pathological hallmarks of
AD become activated and release a cocktail of inflammatory
cytokines and chemokines (Jorda et al., 2020). The systemic
infections and its ability to contaminate macrophages,
microglia and astrocytes in the central nervous system
(CNS) have a particular role (Merad and Martin, 2020).
The viruses and bacteria can activate glial cells and induce
a pro-inflammatory state in the brain (Kanberg et al.,
2020).
Acute infection initiates complex systemic inflammatory
responses as part of the innate immunity (Chen et al., 2020).
An extensive interaction between the brain and the immune
system is present in neurodegenerative diseases (Manson et al.,
2020). These are often triggered in a subcellular compartment
known as the inflammasome, where IL-6 and IL-1 are the
main pathological mediators causing cytokine storm during
acute infection (Mehta et al., 2020). These cytokine-mediated
multisystem inflammatory responses are common in AD, DS,
and other age-related dementia and associated with an increased
risk of severe infection (Kox et al., 2020).
Inflammation is often accompanied by abnormal iron
homeostasis that leads to systemic hypoferritinemia and low
iron levels (Raha et al., 2020). The hypoferritinemia can likely
be due, at least in part, to inflammation-driven increases in
hepcidin concentrations (Litton and Lim, 2019; Hippchen et al.,
2020). How iron homeostasis is maintaining in the whole-body
as well as inside the brain is crucial, yet the mechanism remain
poorly understood.
Ferritin is an iron storage protein. Excess iron stored, in the
form of ferritin protein, is found in many neurodegenerative
diseases, including AD (Smith et al., 1998; Raha et al., 2013).
The age-associated increase in iron stores in the brain tissue
appears to be linked to neuroinflammation (Todorich and
Connor, 2004). Aβ and ferritin co-localize within the vascular
amyloid deposits in the post-mortem AD brain, with iron
accumulation being a ready source of redox generated free
radicals that promote neuronal cell death (Smith et al., 1997;
Atamna and Boyle, 2006; Raha et al., 2013). The understanding
of how iron homeostasis is maintained both at cellular and
whole-body level has exponentially increased following the
identification of a number of iron related proteins, such as
the divalent metal transporter 1 (DMT1), ferroportin (FPN)
and hepcidin (McKie et al., 2001; Ganz, 2003; Hentze et al.,
2010). The liver-derived hormone hepcidin plays a significant
role in host defense and innate immunity due to its broad
antibacterial and antiviral properties (Ganz, 2003). Hepcidin
regulates systemic iron homeostasis by controlling iron flux
into the plasma from the duodenum, as well as through iron
recycling macrophages binding to its receptor, the iron exporter
FPN (Krause et al., 2000; Pigeon et al., 2001; Nemeth et al.,
2004b). Low hepcidin levels cause iron overload, whereas high
hepcidin levels cause anemia of inflammation by restricting
intestinal iron absorption and macrophage associated iron
release (Cheng et al., 2011).
Besides the circulating iron levels, inflammation is another
factor regulating hepcidin transcription in hepatocytes.
Inflammatory cytokines, mainly in the form of IL-6, are
released during inflammation and induce hepcidin expression in
the hepatocytes via the JAK/STAT3 signaling pathway, leading
to phosphorylation of STAT3, its translocation to the nucleus
and the hepcidin gene activation (Pietrangelo et al., 2007;
Eikelenboom et al., 2012b). The inflammation in AD and DS can
therefore be an additional reason for the increase in hepcidin
levels, like that seen in the systemic environment.
To evaluate hepcidin and ferritin expression in controls, AD
and DS subjects, serum and post-mortem brain samples were
analyzed to determine the crosstalk between inflammation and
iron dysregulation in normal ageing, AD and DS pathology.
MATERIALS AND METHODS
Ethics and Participants
Ethics plus research and development (R&D) and approvals
were granted by the National Research Ethics Committee
of the East of England—Norfolk and Cambridgeshire and
Peterborough NHS Foundation Trust, respectively. Cambridge
Health Authorities Joint Ethics Committee granted ethical
approval for the use of human brain tissue and serum samples
(Project ref no.: REC:15/WM/0379). Written consents were
obtained from controls, adult DS participants and subjects with
ADwith the capacity to consent. Verbal assent was obtained from
participants with AD and DS, who lacked the capacity to provide
written assent, and this was provided instead by an appointed
consultee, in accordance with the Mental Capacity Act of the
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UK (2005). Information on older controls (n = 50), younger
controls (n = 50), DS (n = 47) and AD (n = 50) has already
been disclosed in a previous publication (Raha-Chowdhury et al.,
2018).
Assessment of Dementia Status
This was undertaken as described previously using the
CAMDEX-DS informant interview and the CAMCOG-DS
neuropsychological assessment (Annus et al., 2017).
Blood and Serum-Collection
Whole blood and serum samples were collected from younger
human controls (n = 50, aged between 30 and 55 years), and
older controls (n = 50, aged between 56 and 85 years, with
intact cognitive functioning and devoid of neurological
and mental health disease), 47 DS cases (aged between
32 and 70 years) and assessed at our Research Centre. A
cohort of AD cases (n = 50, aged between 56 and 85 years)
was provided by collaborator (co-author, RF) for DNA
and protein analysis. All blood samples were collected for
serum in BD vacutainer SST advance tubes (containing inert
gel barrier and clot activator coating). Serum and plasma
were separated immediately by centrifugation at 2,465 g for
6 min at 4◦C, aliquoted, and stored at –80◦C until analysis.
Biochemical and hematological profiles including serum iron
were analyzed by pathology laboratories at Addenbrooke’s
Hospital, Cambridge University NHS Foundation Trust,
Cambridge, UK.
Human Post-Mortem Brain Sections
Human post-mortem brain tissues from controls (mean age 60±
15 years), DS (mean age 60± 15 years) and AD (mean age 82.0±
8.0 years; n = 10 in each group) were provided by the Cambridge
Brain Bank (Table 1). Cambridge Health Authorities Joint Ethics
Committee granted ethical approval for use of human brain
tissue and serum samples (Project ref no.: REC:15/WM/0379).
Solid-Phase Enzyme Linked
Immunosorbent Assay (ELISA)
The human serum ferritin level was measured with the
human ferritin kit ELISA (Abcam, cat number Ab108698) and
serum hepcidin (human hepcidin Quantikine ELISA kit, cat
number DHP250) and IL-6 (human IL-6 Quantikine ELISA
kit, cat number S6050, R&D) according to the manufacturer’s
instructions. Briefly, for the detection of hepcidin, samples
in 96-wells culture plates were incubated overnight with
monoclonal antibody (R&D, MAB83071) or anti-hepcidin
capture antibody (1 µg/ml; R&D system, cat number 842127).
The following day, the plates were washed three times
with washing buffer [0.05% Tween 20 in 0.1 M phosphate
buffer saline (PBS) pH7.4] and blocked in blocking solution
(1% BSA and 0.05% Tween 20 in 0.1 M PBS) for 2 h
at room temperature (RT). After blocking, the plates were
washed three times with washing buffer and loaded with
10 µl plasma into 90 µl blocking solution and incubated 4
h at RT. All experiments were performed in quadruplicate
unless otherwise specified. A recombinant human protein
(R&D, cat number 842129) was diluted in assay buffer in
a 2-fold serial dilution and used for the standard curve
with a concentration range of 1,000, 500, 250, 125, 62,
31, 15, and 0 pg/ml. After 4 h of incubation, the samples
were removed and the plates were washed three times for
5 min with washing buffer before incubation for 2 hs at
RT for detection with a biotinylated rabbit polyclonal anti-
human hepcidin (Abcam, cat number ab30760) antibody
(1 µg/ml) diluted in blocking buffer. After three further
washing steps, the plates were incubated with anti-rabbit HRP-
conjugated secondary antibody (1:4,000) for 1 h followed
by three washes. One-hundred microliter of 1-Step ULTRA
tetramethylbenzidine (TMB-ELISA, Thermo Fisher Scientific)
was added for ∼30 min at RT. Finally, 100 µl of 2 M H2SO4
was added to quench the reaction. Colorimetric quantification
was performed with an Infinite M200 plate reader (Tecan) at
450/540 nm.
Antibodies
A polyclonal rabbit anti-hepcidin 25 (Abcam ab30760)
recognising a 2.8 kDa protein (Raha-Chowdhury et al.,
2015), human anti-ferritin light chain (Abcam ab69090),
human anti-ferritin heavy chain (Abcam ab65080), Anti-FPN
(Abcam ab85370), anti-GFAP (Abcam ab48050), anti-CD68
(Sigma–Aldrich, MAB98073), and monoclonal anti-Iba1
(Thermo Fisher Scientific, MAB M1/70), Polyclonal anti-
Iba1(Wako cat number 019-19741), monoclonal anti-IL-6
(Thermo Fisher, cat number M620), monoclonal anti-IL-1β
(Thermo Fisher Scientific, cat number ILB1-H67), Anti-β
amyloid (Covance cat number SIG 39320), Anti-Phospho-
Tau (AT8, Thermo Fisher Scientific, cat number MN1020),
was used for IHC. The following secondary antibodies were
used: biotinylated goat anti-rabbit-Ig and biotinylated horse
anti-mouse (both from Vector Laboratories, 1:250 for IHC);
Alexa Fluor 568-labeled donkey anti-mouse-Ig, Alexa Fluor
488-labeled donkey anti-rabbit-Ig, and Alexa Fluor 568-
labeled donkey anti-goat-Ig (all from Invitrogen, 1:1,000 for
immunofluorescence).
Perls Staining Methods for Brain Iron
Perls Prussian blue method was followed for staining ferric iron:
The ferric iron combines with potassium ferrocyanide to form









Paraffin fixed brain sections (n = 6, in glass slides) were
deparaffinized and hydrated with iron free distilled water. The
sections were then transferred to a mixture of equal parts of 2%
potassium ferrocyanide for Perls staining at pH6 and 2% HCL
in distilled water for 20–30 min. The brain sections were then
washed in distilled water. All sections were counterstained in
eosin, dehydrated, and mounted with a synthetic resin medium
(Meguro et al., 2005).
Congo Red Staining for Amyloid Plaques
Congo red stain applied to the tissue gives the amyloid protein
a salmon-pink color and when placed under polarized light,
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TABLE 1 | Characteristics of post-mortem brain samples of Alzheimer’s disease (AD), Down’s syndrome (DS) and age-matched control study population, showing age,
gender, post-mortem time delay, Braak stage and cause of death.
Case number Category Age Gender PM delay (h) Braak stage Cause of death
Down’s syndrome (DS)
DS1 DS 56 F 6 6 Not known
DS2 DS 76 F 18 6 Septicaemia
DS3 DS 46 F 8 2 Not known
DS4 DS 52 M 24 6 Bronchopneumonia
DS5 DS 64 M 31 6 Not known
DS6 DS 66 F 26 5 Not known
DS7 DS 67 M 8 5/6 Alzheimer’s disease (AD), Cerebrovascular
disease (CVD)
DS8 DS 52 F − 6 AD, Lewy body dementia
DS9 DS 52 M − 5 Traumatic brain injury (TBI)
DS10 DS 76 F 18 6 Dementia
Alzheimer’s disease (AD)
AD1 AD 86 F 86 6 Urinary tract infection/Advanced dementia
AD2 AD 88 M 81 6 Urinary tract infection/Addison’s disease and
poor immunity/Vascular and Alzheimer’s
dementia




AD4 AD 88 M 22.3 5 Pneumonia/Aortic stenosis/Mixed
dementia/Left cerebellar hemisphere
haemorrhage
AD5 AD 70 M 71 6 Pneumonia/Alzheimer’s disease
AD6 AD 79 F 45.3 6 Cerebrovascular accident/Dementia
AD7 AD 78 M 62 6 Alzheimer’s disease
AD8 AD 89 M 44 5 Alzheimer’s disease
AD9 AD 78 M 24 4 Alzheimer’s disease
AD10 AD 95 M 61 1 Alzheimer’s disease
Controls
C1 Normal 66 M 10.3 5 Cerebrovascular disease/Dementia
C2 Normal 45 F 43.3 0 End stage renal failure/diabetic nephropathy
C3 Normal 54 F 10.3 0 Metastatic myxoid
liposacroma/Bronchopneumonia
C4 Normal 52 F 30.3 1 Bronchogenic cancer
C5 Normal 75 F 24 2 Cancer of the ovary
C6 Normal 66 F 29.3 2 Metastatic breast cancer
C7 Normal 83 M 45 0 Not known
C8 Normal 68 M 48 0 Not known
C9 Normal 60 F 60 0 Not known
C10 Normal 66 M 74 0 Not known
the amyloid proteins have an apple-green birefringence. This
apple-green birefringence is considered pathognomonic for
amyloid fibril deposits (Howie et al., 2008). Congo red was
purchased from Sigma–Aldrich (cat number C6277). It is an
organic compound, a sodium salt of 3,3′-[(1,1′-biphenyl)-4,4′-
diyl]bis(4-aminonaphthalene-1-sulfonic acid) and is an azo dye.
Congo red is water-soluble, yielding a red colloidal solution.
Paraffin fixed human brain sections (n = 6, in glass slides)
were deparaffinized and hydrated with iron free distilled water.
The brain sections were then immersed in Congo red dye for
10 min and rinsed thereafter in distilled water. The sections were
differentiated quickly (5–10 dips) in alkaline alcohol solution
and rinsed in tap water. Slides were counterstained in Gill’s
hematoxylin for 30 s and mounted with a synthetic resin
medium.
Immunohistochemistry (IHC)
Paraformaldehyde (PFA) fixed tissues were first quenched with
5% hydrogen peroxide and 20% methanol in 0.01 M PBS for
30 min at RT followed by three rinses for 10 min in 0.01 M
phosphate buffer saline (PBS). Non-specific binding sites were
blocked using blocking buffer (0.1 M PBS, 0.3% Triton-X 100,
and 10% normal goat serum for polyclonal antibodies or 10%
normal horse serum for monoclonal antibodies) for 1 h at
RT. Tissue sections were incubated overnight with the primary
antibody diluted in blocking buffer. Binding of the primary
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antibody was detected using a biotinylated secondary antibody
followed by an avidin-biotin complex conjugated to peroxidase
(Elite standard kit SK6100, Vector Laboratories) and DAB
substrate (ABC substrate SK-4200, Vector Laboratories).
Immunofluorescence (IF)
Brain and other sections were blocked using blocking buffer
(0.1 M PBS, 0.3% Triton X 100, 10% normal donkey serum) for 1
h at RT, then incubated overnight at 4◦C with primary antibody
diluted in blocking buffer. Alexa Fluor-conjugated secondary
antibodies were used for detection and samples counterstained
with 4′6-diamidino-2-phenylindole (DAPI, Sigma). The sections
were then mounted on glass slides with coverslips using Fluoro
Save (Calbiochem).
Microscopy
Bright field images were taken and quantified using Lucia
imaging software and a Leica FW4000 upright microscope
equipped with a SPOT digital camera. Fluorescence images
were obtained using a Leica DM6000 wide field fluorescence
microscope equipped with a Leica FX350 camera with 20×
and 40× objectives. Images were taken through several z-
sections and de-convolved using Leica software. A Leica TCS SP2
confocal laser-scanning microscope was used with 40× and 63×
objectives to acquire high-resolution images.
Image and Statistical Analysis
Data were analyzed by paired Student’s t-test (two-tailed) for two
group comparison, or by ANOVA test for multiple comparison
testing. Values in the figures are expressed as mean ± SEM.
A one–way ANOVA was used for comparison of data among
control, AD and DS and conducted with IBM-SPSS statistic
19 software. Significance was analyzed using GraphPad and p-
values ≤0.001 were considered significant and are indicated in
the corresponding figures and figure legends.
RESULTS
Significant Elevation of Serum Hepcidin in
DS Subjects
We investigated serum iron, ferritin and hepcidin levels in
AD, DS and age-matched control subjects with sandwich
ELISA. Serum iron was measured by clinical biochemistry,
at the Addenbrooke’s Hospital of Cambridge University NHS
Foundation Trust located in Cambridge, UK. All samples were
analyzed on the same day, using same standardized protocol to
reduce the day-to-day variation.
Serum iron levels were significantly higher (p < 0.0001)
in control subjects (25.07 ± 5.06 µmol/L) compared to AD
(16.2 ± 9.2 µmol/L) and DS (15.42 ± 10.1 µmol/L; Table 2,
Figure 1A). Similarly, serum ferritin levels were significantly
higher (p < 0.0001) in controls (216.9 ± 171.1 µg/L), compared
to AD (149.4 ± 199.5 µg/L) and DS (133.82 ± 85.7 µg/L;
Figure 1B). In contrast, hepcidin levels were substantially higher
(p < 0.0001) in DS (mean± SD: 188.32± 430.5 µg/L) compared
to AD (36.3 ± 18.2 µg/L) and controls (25.38 ± 22.1 µg/L;
Figure 1C). The iron and ferritin level in control subjects
indicated that iron and ferritin stored were within normal range
as expected (Figure 1D). To evaluate that ferritin and hepcidin
levels were not reflecting the age, we analyzed age matched
controls (ages between 65–85 years) and AD subjects. We found
that serum ferritin was significantly higher in aged controls
compared to AD (p < 0.0001), whereas hepcidin levels were
lower in AD (Figure 1E). However, hepcidin levels were high
in DS compared to controls and AD individuals suggesting
inflammatory changes or impaired dis-erythropoiesis affecting
the DS subjects (Figures 1D,E).
Iron Accumulation Is Visible in DS Senile
Plaques
DS brain sections from superior frontal gyrus (SFG), mid
temporal gyrus (MTG), and hippocampus (HP) were then
analyzed by immunohistochemistry (IHC) using antibodies
specific to Aβ42 (6E10), Phospho-tau (AT8), hepcidin and
ferritin heavy chain (FTH) using DAB stain. In the SFG
from DS brain, abundant Aβ42 positive plaques were observed
in the neocortex (Figures 1F,G, black arrows highlight the
selected area of plaques formed) and very close to and even
inside the blood vessels (Figure 1I). To confirm neurofibrillary
(neuritic) plaque formation, a representative section from DS
brain was stained with Congo red (Figure 1H). Congo red
stain recognized the amyloid protein appearing as salmon-
pink color and when placed under polarized light, the amyloid
proteins had an apple-green birefringence. This apple-green
birefringence is considered pathognomonic for amyloid fibril
TABLE 2 | Characteristics of AD, DS and age matched control study population used to measure serum iron, ferritin, hepcidin, and IL-6.
Characteristic Controls N = 50 AD N = 50 DS N = 47 Significant p-value
Males, n (%) 25 (50%) 25 (50%) 30 (60%) 25 (53%)
Females n (%) 25 (50%) 20 (4%) 22 (47%)
Age 50 ± 27 72 ± 23 47 ± 22
Older controls N = 50, 65± 20
Iron parameters
Serum iron (µmol/L) 20.18 ± 5.1 15.4 ± 10.1 16.6 ± 9.9
Serum Ferritin (µg/L) 212.67 ± 72.6 140.5 ± 231.1 133.82 ± 331.5 <0.0001
Serum Hepcidin (µg/L) 25.35 ± 26.6 36.3 ± 51.2 188.32 ± 430.9 <0.0001
Serum IL-6 (pg/ml) 66.23 ± 70.5 378.51 ± 201.89 304.03 ± 330 <0.0001
Data are expressed as number of patients (percent), mean ± SD. Probability value (p) denote difference among control, AD and DS patient groups. One-way analysis of variance
(ANOVA) was used to compare age between groups and statistical analysis was measured with Mann–Whitney U test.
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FIGURE 1 | Significant elevation of serum hepcidin in Down’s syndrome (DS) subjects and iron accumulation visible in DS senile plaques. Human serum from
Alzheimer’s disease (AD), DS and age-matched control subjects showing iron (A), ferritin (B), and hepcidin (C; “Materials and Methods” section described in main
text). Scattered plot showing levels of serum iron (A) and serum ferritin (B) significantly higher in control subjects compared to AD and DS (p < 0.0001). In contrast,
hepcidin levels were substantially higher in DS compared to AD and controls (p < 0.0001; C). Comparison of iron, ferritin and hepcidin level showing highest hepcidin
levels in DS when compared to controls and AD individuals (D). Serum samples from AD and age matched older controls (OC) on comparison showed the highest
ferritin levels in OC compared to AD, whereas there were no significant differences in hepcidin levels (E). Statistical differences were calculated by Mann–Whitney U
test. **p < 0.001, ***p < 0.0001 and ****p < 0.00001. DS brain sections from superior frontal gyrus (SFG) stained with DAB and anti-Aβ42 antibody revealed strong
signal of SPs positive for Aβ42 and visible throughout the cortex (F, black arrows highlighting the selected area of plaques formation, (G) in higher magnification
inside the plaque formation and (I) close to the blood vessels. To confirm neurofibrillary (neuritic) plaque formation, a representative section was stained with Congo
red (H) showing the amyloid proteins having apple-green birefringence under polarized light in senile plaques (SP). Perls’ stain identifies the ferric (Fe3+) form of iron,
showing limited ferric iron was visible albeit only in the glial cells periphery of senile plaques (J), and in controls particularly seen in neuromelanin cells of substantia
nigra pars compacta (SNPC) in controls (K). Similarly, a section from mid temporal gyrus (MTG) was stained with phospho-tau (AT8) showing neurofibrillary tangle
close to glial cells (L), and some of those neuro-filaments were ferritin (FTH) positive (M). In the hippocampus of DS brain section, granule cells were positive for
hepcidin (N). Scale bar: (F and I) = 200 µm, (L–N) = 50 µm, (G,H,J,K) = 25 µm.
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deposits (Figure 1H). Similarly, a section fromMTG was stained
with phospho-tau (AT8) showing neurofibrillary tangle (NFT),
close to glial cells (Figure 1L), and some of those neuro-
filaments were ferritin (FTH) positive (Figure 1M). In the DS
hippocampus, some granule cells were positive for hepcidin
(Figure 1N).
To confirm if iron accumulation in the brain tissues were
stained with Perls stain to identify ferric form (Fe3+), we
followed the procedures described in previous publications
(Morris et al., 1992; Meguro et al., 2007), and compared the iron
accumulation in aged normal and DS subjects (brain sections
from cortex and substantia nigra pars compacta (SNPC) stained
with Perls stain). In DS brain, presence of very faint ferric
iron was seen around the SP (Figure 1J), whereas strong iron
accumulation was seen in the SNPC (in neuromelanin cells;
Figure 1K) as reported before (Morris et al., 1992; Meguro et al.,
2007).
Hepcidin Protein Accumulates Around the
Senile Plaques in AD and DS Brains
Brain sections from the hippocampus, entorhinal cortex and SFG
were then analyzed by IF and imaged with confocal microscopy,
using antibodies specific to Aβ42 (6E10) and hepcidin. Sections
of AD SFG when stained for hepcidin (green) and Aβ42 (red),
showed senile plaques recognized by Aβ42 and hepcidin staining
was seen in the neuropil and fibrillary structures (Figures 2A–C).
In DS brain, abundant Aβ42 positive cotton wool appearance
of senile plaques (SP), close to the blood vessels were observed.
In DS SFG, very limited hepcidin positive glial cells were seen
in the periphery of plaques (Figures 2D–F). Contrastingly, in
control brains (i.e., SFG), abundant hepcidin positive cells were
present (Figures 2G,H) wherein the two proteins Aβ42 and
hepcidin showed co-localization near the blood vessels, while
hepcidin filaments were predominantly located in the astrocytes
(Figure 2H).
Hepcidin and Ferritin Expression in
Astrocytes Close to the Blood Vessels
As described above, hepcidin was observed in the astrocytes
in the disease affected brains. We, therefore, evaluated the
expression of hepcidin in sections from the MTG, sub
ventricular zone (SVZ) and close to the blood vessels of
cortex (SFG). In DS brain, GFAP positive activated astrocytes
were present around the SP and surrounding the blood
vessels (Figures 3A,B, indicated with an arrow or filled
circle).
Hepcidin expression was visible in the periphery of
blood vessels (in the endothelial cells) and co-localized
with the GFAP positive astrocytes in the DS and AD brains
(Figures 3C,E,F). In the DS and AD brain, particularly in
the SVZ and near the blood vessels, a large number of small
vesicles carrying hepcidin were present and co-localized
with GFAP positive astrocytes (Figures 3D,E). Similarly,
in the AD brain, astrocytes were present surrounding the
blood vessels and co-localized with the ferritin light chain
(FTL; Figure 3F). Furthermore, from the SFG section of
controls, it appeared that soluble hepcidin entering from
blood vessels may have been delivered via the red blood
cells (Figure 3G), whereas ferritin (FTL) may have entered
through the macrophages/microglia but did not co-localize
with hepcidin close to the blood vessels (Figure 3G). In
contrast, hepcidin was present in the pyramidal neurons in the
hippocampus of a normal control brain and showed limited
co-localization with FTL in the periphery of the neurons
(Figure 3H).
Selective Population of Microglia and
Meningeal Macrophages Are Involved in
Brain Iron Homeostasis in DS
Hepcidin and ferritin could be involved in microglial activity
and in the amyloid clearance process (Raha et al., 2013;
Raha-Chowdhury et al., 2015). To assess this aspect, we
extended our investigation of hepcidin expression in microglia
and macrophages in control, AD and DS brain samples
(n = 10 from each group, Table 1) with a particular focus on
identifying hepcidin expression in the Iba1 positive microglia.
The brain sections from AD, DS and controls were stained
with microglial marker (Iba1) and hepcidin. In control brains,
Iba1 positive ramified microglia were visible in the cortex
and in the blood vessels. There was a limited co-localization
with hepcidin in some cells but not with Iba1 positive
microglia (Figures 4A–C). In the AD brain, sections from
the dentate gyrus (DG), where most of the granule cells
were damaged, Iba1 positive activated microglia were present
close to the neurons, whereas hepcidin expression was visible
only in the damaged granule cells with limited co-localization
(Figures 4D–F). These findings indicate that there are different
populations of microglia sub-types present in the human brain.
To evaluate the effects of inflammatory changes in different
microglia, another brain section from AD (MTG) was stained
with Iba1 and pro-inflammatory marker IL-1β. Both proteins
co-localized in the small plaques and activated microglia
(Figure 4G). Similarly, a DS brain section, when stained with
Iba1 and hepcidin, Iba1 positive microglia was visible close to
blood vessels but there was no co-localization with hepcidin
(Figures 4H,I).
As previously reported, the choroid plexus (CP) is damaged
in AD brain and as CP is a conduit between the peripheral
circulation and central nervous system via the cerebrospinal fluid
(Raha-Chowdhury et al., 2019). We extended our investigation
to CP sections from DS brain, and stained with hepcidin
and CD68 (a phagocytotic macrophages/microglia marker).
Hepcidin protein was present in the lateral ventricles in a
monolayer of epithelial cells of the choroid plexus and CD68 was
found in the macrophages close to CP and their co-localization
was observed (Figure 4J). These findings suggest that hepcidin
might be transported through exosomes or other small vesicles
and via macrophages to the brain parenchyma. To investigate
this phenomenon, another section from AD brain close to
the lateral ventricle was stained with CD68 and hepcidin. A
large number of CD68 positive peri-vascular macrophages were
visible around the lateral wall of the 4th ventricles that co-
localized with hepcidin, at the endothelial margin (Figure 4K).
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FIGURE 2 | Hepcidin protein accumulates around the senile plaques in AD and DS brains. AD and DS brain sections from the SFG were labeled with double
immunofluorescence using anti-Aβ42, anti-hepcidin and counterstained with 4′6-diamidino-2-phenylindole (DAPI) for nuclei (blue) and imaged with confocal
microscopy. In AD brain, hepcidin staining was visible in the neuropil and fibrillary structures close to the Aβ42 positive senile plaques (SP) (A–C), white arrows
highlighting the selected areas with hepcidin in neuropil and Aβ42 staining in the SP). In DS brain, abundant Aβ42 positive cotton wool appearance of SP, close to
the blood vessels were observed, while very limited hepcidin positive glial cells were present in the periphery of plaques (D–F). In contrast, control brains showed
co-localization of Aβ42 and hepcidin near the blood vessels (G), while hepcidin predominated in the astrocytes located in the periphery of the glial cells (H). Scale
bar: (A–H) = 25 µm.
Frontiers in Aging Neuroscience | www.frontiersin.org 8 April 2021 | Volume 13 | Article 653591
Raha et al. Impaired Iron Homeostasis in Neuroinflammation
FIGURE 3 | Hepcidin and ferritin expression in astrocytes close to the blood vessels. AD and DS brain sections from the MTG, sub ventricular zone (SVZ) and close
to the blood vessels of cortex (SFG) were labeled with double immunofluorescence using anti-hepcidin (green), anti-GFAP or ferritin light chain (FTL; red) and
counterstained with DAPI for nuclei (blue) and imaged with confocal microscopy. In DS brain, GFAP positive activated astrocytes were present around the SP and
surrounding the blood vessels (A–B, indicated with an arrow). Hepcidin expression was visible in the periphery of blood vessels (in the endothelial cells) (C), and
co-localized with the GFAP positive astrocytes in the DS and AD brains (D,E,F). In the DS brain, particularly in the SVZ, large numbers of small vesicles
(Continued)
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FIGURE 3 | Continued
carrying hepcidin were present and co-localized with GFAP positive
astrocytes (D), and near the blood vessels in AD brain (E). The end-feets of
astrocytes were surrounding the blood vessels and co-localization with the
FTL (green) was visible in the blood vessels (F). In controls, brain section from
SFG when labeled with hepcidin and FTL, both proteins were visible in
different cells close to the blood vessels, hepcidin most probably in the red
blood cells and FTL in the macrophages/microglia (G). In contrast, control
brain (in the hippocampus) showed hepcidin to be present in the pyramidal
neurons, showing limited co-localization with FTL (H). Scale bar:
(A–H) = 25 µm.
Previously, we have shown in the mouse brain that macrophages
are present on the pial surface (Raha et al., 2017). We further
analyzed a cortical section from DS brain and stained with
CD68 and hepcidin. The granular hepcidin protein was visible
in the glial cells inside cortical layers I and II and CD68 was
visible in the meningeal macrophages (Figure 4L). These data
support the notion that soluble and vesicular hepcidin could
be transported via macrophages and blood vessels into the
brain parenchyma.
IL-6 Could be Involved in Host Defense in
AD and DS-Brain
As we have seen, macrophages play a significant role in enabling
iron to enter the plasma compartment. During infection and
inflammation, IL-6 and other cytokines aid to increase the
synthesis of hepcidin leading to sequestration of iron in the
macrophages (Ganz, 2012). The increased levels of hepcidin
in the serum described above (in Figure 1C), led us to
measure serum IL-6 in AD, DS and controls and compare
these results with serum hepcidin (Figures 5A,B). Serum IL-
6 levels were significantly increased in AD compared to old-
age-matched controls (Figure 1B) and in DS participants
(Figure 1A, p < 0.0001). In controls, however, serum IL-
6 level was lower than AD and DS subjects, suggesting that
serum IL-6 could be involved in host defense mechanism
in neuroinflammation (Figures 5A,B). We have also shown
that expression levels of iron proteins (ferritin, hepcidin) are
very different in the brain parenchyma compared to the
periphery (in serum; Raha et al., 2013). DS brain sections
were stained for Aβ42 and ferritin heavy chain (FTH).
Both proteins were found to be co-localized close to the
blood vessels, but FTH positive glia was only visible in
the SP and did not co-localize with Aβ42 positive cells
(Figure 5C). We had previously reported that in the rat
brain, hepcidin and FPN expressed in the white matter
tract (WMT) of corpus callosum (CC) and was involved in
myelination (Raha-Chowdhury et al., 2015). In control brain,
hepcidin protein expression was visible in the WMT (in the
oligodendrocytes), whereas IL-1β was present in the microglia
with minimal co-localization (Figures 5D–F). Brain sections
from AD hippocampus (HP) and DS (SFG) when stained
for hepcidin and IL-1β, revealed similarly the presence of
hepcidin (punctate, vesicular appearance) in the hippocampal
neurons, whereas IL-1β was visible only in the microglia
with minimum co-localization (Figures 5G,H). Similarly, when
control and DS brain sections of HP and SFG were stained
for hepcidin and IL-6, there was less IL-6 visible in the
control brain (Figure 5I), whereas there was a higher co-
localization in the granule cells of HP in DS subjects
(Figures 5J–L) suggestive of hepcidin and proinflammatory
cytokines (IL-1β and IL-6) being involved in host defense
during neuroinflammation.
DISCUSSION
Alzheimer’s disease, Down’s syndrome and age associated
dementia leads to a variety of inflammatory symptoms, and
disproportionately endangers people with pre-existing chronic
conditions including cardiovascular disease, diabetes mellitus,
hypertension, and age-related frailty (Friedland and Haribabu,
2020; Raha et al., 2020; Mukaetova-Ladinska et al., 2021). These
populations are not only at a high risk for chronic infection,
but also of prevalent SARS-COV-2 infection (Wright et al.,
2008). Iron metabolism and anemia may additionally play an
important role in multiple organ dysfunction syndrome such as
that seen in SARS-COV-2 (Gómez-Pastora et al., 2020; Taneri
et al., 2020).
Iron is an essential nutrient for almost all living organisms
but when in excess, it is toxic and regulatory mechanisms have
evolved to ensure that iron homeostasis is maintained at both
the whole-body and cellular levels (Hentze et al., 2010). Ferritin,
a highly conserved iron-binding protein and storage for iron,
has emerged as a key molecule in the immune system, playing
an important role in cellular defense against inflammation
(Raha-Chowdhury et al., 1996). Iron is required for synthesis
of many key enzymes, including myelin and neurotransmitter
production. There are extensive interactions between the brain
iron accumulation and the innate immune system in AD and
other neurodegenerative diseases (Wright et al., 2008).
Hepcidin has emerged as the key regulatory molecule that
controls systemic iron homeostasis in mammals (Krause et al.,
2000; Park et al., 2001; Pigeon et al., 2001). Hepcidin is
synthesized by the liver and regulates the delivery of iron into
the circulation from macrophages, duodenal enterocytes and
hepatocytes (Ganz and Nemeth, 2011). Hepcidin achieves this
level of control by binding to FPN which is the only known iron
exporter expressed by mammalian cells (Nemeth et al., 2004b).
On binding with FPN at the cell surface, hepcidin triggers the
internalization, ubiquitinoylation and lysosomal degradation of
the complex thus limiting cellular iron export (Rivera et al.,
2005).
Macrophages also play a key role both in iron homeostasis
and in a vast range of biological activities, such as cellular
development, scavenging and recycling, tissue repair and host
defense (Pollard, 2009). The release of iron from macrophages
into plasma, in response to systemic iron requirements, is
managed via the interaction of hepcidin with its exporter
FPN. In humans, macrophages contribute to most of the
iron entering the plasma compartment. During infection and
inflammation, cytokines, including IL-6, increase the hepcidin
synthesis and cause iron sequestration in macrophages (Nemeth
et al., 2004a). The resulting decrease in iron availability in
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FIGURE 4 | Selective population of microglia and meningeal macrophages are involved in brain iron homeostasis in DS. The brain sections from controls, AD, and
DS subjects were labeled with hepcidin and microglial marker (Iba1) or macrophages marker CD68, and counterstained with DAPI for nuclei (blue). Hepcidin was
seen in the vesicles, most probably entering from blood vessels and IbaI positive ramified microglia, colocalized in the control cortex (A–C). In AD brain dentate gyrus
(DG), showing IbaI positive activated microglia (D), whereas hepcidin was present in the DG granule cells not in the damaged microglia (E) with no visible
co-localization (F). Iba1 positive microglia may be involved in pruning and clearance of damage cells, where hepcidin protect the granule cells from further damage
(F). Brain section from AD (MTG) stained with Iba1 and pro-inflammatory marker IL-1β showing both proteins to be co-localized in the small plaques and activated
(Continued)
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FIGURE 4 | Continued
microglia (G). Cellular damage in this brain section was substantial (G).
Similarly, in DS brain section from MTG, IbaI positive activated microglias
being present close to the blood vessels (H), but without any co-localization
with hepcidin (I). In DS brain, hepcidin protein was visible in the lateral
ventricles in a monolayer of epithelial cells of the choroid plexus (CP) and
CD68 was found in the macrophages close to epithelial cells of CP
suggestive of involvement in transport of serum proteins from macrophages
to the brain parenchyma (J). AD brain tissue sections when stained with
CD68 and hepcidin show a large number of CD68 positive peri-vascular
macrophages visible around the lateral wall of the 4th ventricles co-localizing
with hepcidin at the endothelial margin (K). Similarly, a cortical section from
DS labeled with CD68 and hepcidin, show granular hepcidin protein visible in
the glial cells inside the cortical layers I and II and CD68 visible in the
meningeal macrophages in the meninges (L). These finding support the
notion that soluble and vesicular hepcidin could be transport via
macrophages and blood vessels into the brain parenchyma (J–L). Scale bar:
(A–I) = 50 µm, (J–K) = 70 µm, (L) = 20 µm.
tissues can limit the growth and pathogenic impact of invading
extracellular microbes, providing an important means of host
defense (Ganz, 2012).
The aim of this study was to investigate the expression of
iron proteins ferritin and hepcidin, in AD and DS serum and
compare these protein levels in brain parenchyma in normal
and dementiarelated diseased brain and discuss these findings
in relation to the reported hyperferremia in SARS-COV-2
infected patients (Dahan et al., 2020; Gómez-Pastora et al., 2020;
Hippchen et al., 2020; Zhou et al., 2020). These findings may
explain why people with AD andDS are at a higher risk for SARS-
COV-2 infection.
We reported that serum iron and ferritin levels were
significantly higher in normal controls compared to AD and DS
participants. In contrast, the hepcidin levels were 20 times higher
in DS than those detected in AD and controls suggesting the
presence of inflammatory changes or dis-erythropoiesis affecting
especially the DS subjects.
Using IHC, we analyzed brain iron and other proteins (i.e.,
ferritin and hepcidin) from AD subjects, and compared with
our previously published work on AD brain and transgenic
mouse model of AD (APP-PS1; Raha et al., 2013). In the DS
brain, abundant Aβ42 positive plaques were present in the
neocortex, similar to those seen in AD brain, and additionally
when stained with Congo red showed the existence of fibrillary
birefringence in SP, and Perls stains in glial cells, indicating
the presence of iron in the SP of DS brain as previously
reported (Morris et al., 1992; Howie et al., 2008). We have noted
amyloid deposition within blood vessels signifying presence
of cerebral amyloid angiopathy which is widely reported in
almost all DS brains. We noted several meningeal vessels were
positive for Aβ42 (Figure 1I). In Figures 2D–F, DS brain section
stained with Aβ42 and analyzed by confocal microscope, showed
amyloid expression in the blood vessel walls too. Similarly, in
Figure 3C (hepcidin in the blood vessels) and 3F (FTL within
blood vessel walls), and Figure 1I showed Aβ42 deposit in the
blood vessels.
All DS subjects had aneuploidy, i.e., carried an extra copy
of chromosomes 21, where APP gene is encoded. DS subjects
do produce a much higher amount of amyloid β protein due
to carrying an extra copy of APP gene, that subsequently
produce excess amount of Aβ affecting its clearance from
the blood vessels (Raha et al., 2013; Raha-Chowdhury et al.,
2018). Our IHC analysis indicated that amyloid plaques were
carrying ferritin in the core of SP, and consequently the iron
accumulation could lead to increase in oxidative stress in
DS subjects.
In the neocortex of AD and DS subjects, Aβ42 positive
SPs were visible close to the blood vessels, while hepcidin
predominated in the GFAP positive astrocytes in granular form
and in the endothelial cells of blood vessels. Similarly, in AD
brain, astrocytes were present surrounding the blood vessels and
co-localized with FTL. These findings support the notion that
astrocytes have a task in iron transport in the brain parenchyma.
FTL and hepcidin may enter the brain from the periphery via
blood vessels or could even export proteins from the brain
parenchyma to the peripheral circulation.
Hepcidin and ferritin are also involved in microglial activity
and the amyloid clearance process (Raha et al., 2013; Raha-
Chowdhury et al., 2015). In AD brain section, Iba1 (a microglial
marker) positive activated microglia were present close to the SP,
whereas hepcidin expression was visible in the damaged granule
cells of dentate gyrus (DG) but did not co-localize with Iba1.
These findings indicate that there are different population of
microglial sub-types present in the human brain and some of
the Iba1 positive activated microglia are involved in pruning and
clearance of dead cells, and co-localize with pro-inflammatory
marker IL-1β but not with hepcidin. Our observations support
previously reported notion that hepcidin also has a special role
in repair and regeneration of glial cells and neural plasticity
(Forostyak et al., 2020).
Previously, we have reported that the choroid plexus (CP)
is damaged in AD brain, and CP is a conduit between the
peripheral circulation and the central nervous system via the
cerebrospinal fluid (Raha-Chowdhury et al., 2019). Our findings
of hepcidin (present in a monolayer of cuboidal epithelial
cells of the CP) and CD68 (present in the macrophages close
to CP) and their colocalization, as well as their ventricular
and cortical localization, support the notion that soluble and
vesicular hepcidin could be transported both via different
population of macrophages (CP, perivascular and meningeal
macrophages) and via the blood vessels in to the brain
parenchyma (Kalaria et al., 1996).
The hyperinflammatory response induced by SARS-CoV-2
through peripheral macrophages is a major cause of disease
severity (Cohen et al., 2010). This population of innate immune
cells sense and respond to microbial threats by producing
inflammatory molecules that eliminate pathogens and promote
tissue repair. A dysregulated macrophage response, however, can
be damaging to the host, as seen in the macrophage activation
syndrome induced by severe infections, including SARS-CoV-2
(Otsuka and Seino, 2020).
Microglia in the vicinity of the SP and NFT in AD/DS become
activated and release a cocktail of inflammatory cytokines and
chemokines (Akiyama et al., 2000). The persistence of infection
and its impact on macrophages, microglia and astrocytes in the
CNS are particularly important since a neurotropic virus can
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FIGURE 5 | IL-6 could be involved in host defense in AD and DS brain. ELISA based analysis of IL-6 in serum samples showing increased levels in AD and highest
level in DS when compared with hepcidin (p < 0.0001; A). Samples were analyzed from AD and age matched older controls (OC), IL-6 levels were significantly higher
in AD serum (B; p < 0.0001). Ferritin (FTH) was present close to a SP in DS brain analyzed by double immunofluorescence, and did not co-localize with Aβ42
positive plaques (C). Another control brain section from white matter tract (WMT) of corpus callosum (CC), labeled with hepcidin, expression being visible in the WMT
(in the oligodendrocytes), whereas IL-1β being present in the microglia with minimal co-localization (D–F). Brain sections from AD (HP, hippocampus) and DS (SFG)
when stained with hepcidin and IL-1β, revealed similarly the presence of hepcidin (punctuate, vesicular appearance) in the hippocampal neurons, whereas IL-1β was
visible only in the microglia with minimum co-localization (G,H). When control and DS brain sections of HP and SFG were stained for hepcidin and IL-6, there was
less IL-6 visible in the control brain (I), whereas there was a higher co-localization seen in the granule cells of hippocampus of DS subjects (J–L). Scale bar: (C and
G) = 20 µm, (D–F) = 50 µm, (H–L) = 25 µm. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
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activate glial cells and induce a pro-inflammatory state (Kanberg
et al., 2020).
Inflammation in AD and DS could further be a reason
for the increase in hepcidin levels as noticed in the systemic
environment. Besides the iron levels present in the circulation,
inflammation is yet another factor regulating hepcidin
transcription in the hepatocytes. Inflammatory cytokines,
mainly in the form of IL-6, are released during inflammation and
induce hepcidin expression in the hepatocytes (Pietrangelo et al.,
2007; Eikelenboom et al., 2012a). IL-6, a major highly inducible
pro-inflammatory cytokine, is secreted by many different
cell types including monocytes, lymphocytes, fibroblasts, and
endothelial cells (Zegeye et al., 2018).
Not surprisingly, we confirmed increased serum IL-6 levels in
AD and DS subjects, while controls had IL-6 levels lower than
that of ferritin suggesting that serum IL-6 could be involved in
host defense in AD and DS. An increased serum level of IL-6
is linked to severity (Ulhaq and Soraya, 2020a) and increased
fatality in SARS-COV-2 (Chan et al., 2020), as well as respiratory
dysfunction (Ulhaq and Soraya, 2020b). Similar findings have
now been reported using profiling plasma proteomics that not
only identified IL-6 to be among the most perturbed proteins in
SARS-COV-2 patients but also confirmed it as an indicator of
disease severity. In addition, the rapid replication of SARS-CoV-
2 triggers elevated IL-6 production that can lead to heightened
respiratory distress. Therefore, IL-6 stands as a possible common
biomarker for AD/DS and SARS-COV-2 (Hüll et al., 1996).
Levels of IL-1 have also been reported to have increased in AD
and DS patients (Griffin et al., 1989). IL-1 has been noticed to
be significantly higher in the SARS-COV-2 patients too during
the disease onset as well as throughout the duration of disease
progression (Cavalli et al., 2020).
Apolipoprotein E is the main carrier of cholesterol in the
central nervous system (CNS) and an important constituent
of very low–density lipoproteins (VLDL). Among its three
alleles (ε2, ε3, and ε4), the individuals carrying the ε4 allele
are at a higher risk of developing AD since the ApoE ε4/ε4
genotype increases fibrinogenesis in the brain of Alzheimer’s
disease patients (Hultman et al., 2013; Raha-Chowdhury et al.,
2018). In our DS cohort, more than 25% subjects were carrying
heterozygous ApoE ε4 allele and interestingly all such subjects
had higher serum IL-6 levels (average 465.85 pg/ml) compared
to the DS subjects carrying ApoE ε2/ε3 allele (average 129.93
pg/ml; Henderson et al., manuscript is in progress). Recently,
ApoE ε4 has been regarded as a marker that could be indicative
of increasing severity risk in SARS-COV-2 (Kuo et al., 2020).
Our findings of higher inflammatorymarkers in ApoE ε4 carriers
provide further evidence to suggest that AD and DS patients
carrying the ApoE4 allele are at a heightened risk of developing
SARS-COV-2 infection.
Older people are at a higher risk of falling victim to
both AD dementia and SARS-COV-2 infection. Although DS
subjects are usually younger than AD subjects, they suffer
from accelerated ageing and neuroinflammation that itself are
additional risk factors for SARS-COV-2 infection. Heightened
production of reactive oxygen species (ROS), iron accumulation,
exacerbated production of amyloidβ, its aggregation and
consequent neurodegeneration, perturbed lifestyle modification
have all been implicated in the pathogenesis of AD, and all such
comorbidities also place them at a higher risk for SARS-COV-2
infection.
CONCLUSION
AD and DS subjects are likely to be both at a higher
risk for SARS-COV-2 infection due to dis-balance in iron
homeostasis and failure of amyloid protein clearance leading
to neuro-inflammation. Macrophages plays a key role in iron
homeostasis, regulating passage of iron proteins between the
brain parenchyma and the peripheral circulation. Macrophages
are a population of innate immune cells that sense and respond
to microbial threats by producing inflammatory molecules
that eliminate pathogens and promote tissue repair. DS, AD
and SARS-COV-2 share common links with respect to iron
proteins, hepcidin, ferritin and pro-inflammatory markers
such as interleukin-1 (IL-1β), IL-6, and ApoE ε4 allele.
Hepcidin, ferritin and IL-6 participate significantly towards
host defense mechanism associated with neuroinflammation.
Such mechanisms could well be implicated in SARS-CoV-2
infection and objective evaluation of perturbed iron homeostasis
may be indicative of how severely someone may be infected
by SARS-CoV-2.
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